In the absence of excretory function, patients with endstage renal disease depend on regular potassium removal by dialysis to avoid life-threatening hyperkalemia, Severe hyperkalemia with electrocardiographic changes in such patients requires emergency hemodialysis to remove excess potassium (1, 2) . Because of the inevitable delays in starting dialysis, a number of temporizing measures are required. Calcium gluconate (10-20 ml by intravenous bolus) stabilizes the myocardium and improves the electrocardiographic abnormalities without affecting plasma potassium. Further measures are indicated to shift potassium temporarily from the extracellular to the intracellular fluid compartment, thereby decreasing plasma potassium acutely. This shift can be achieved by intravenous insulin (10 units regular insulin + 50 ml of 50% dextrose to prevent hypoglycemia) (3, 4) and the beta-2 adrenergic agonist albuterol (0.5 mg IV bolus or 10-20 mg nebulized over 10 minutes) (3) (4) (5) (6) . Nebulized albuterol is as effective as intravenous albuterol in lowering plasma potassium acutely but is better tolerated (7). The potassium lowering effects of insulin and abuterol are additive (3, 4) . Intravenous sodium bicarbonate was frequently advocated in the past to lower plasma potassium acutely. However, the earliest decrease in plasma potassium occurs 4 hours after bicarbonate administration (8, 9) , rendering this modality unreliable in the acute setting.
Potassium removal during dialysis has been poorly characterized. Total potassium removal is the sum of removal due to ultrafiltration and to dialysis. The former accounts for only 15% of total potassium removal and depends primarily on the volume of ultrafiltration (10) . Dialytic removal (-50 mmol during an average session) accounts for the remaining 85% and is largely determined by the blooddialysate potassium gradient (10) (11) (12) (13) . Plasma potassium decreases rapidly in the first hour of hemodialysis, at a slower rate in the second hour, and remains fairly constant during the remainder of the dialysis session (10, 11) . Because the dialysate potassium concentration is constant throughout the dialysis, the large initial blood-dialysate concentration gradient diminishes progressively in the first 1 to 2 hours of dialysis, so that potassium removal declines over time (10) . Early in dialysis the major source of dialyzed potassium is from the extracellular fluid compartment. During the latter part of dialysis the rate of potassium shift from the intracellular to the extracellular fluid compartment matches the rate of removal from the blood to the dialysate, so that the potassium removed is derived largely from the intracellular pool (10, 11, 13) . Lowering dialysate potassium increases potassium removal, but also results in a lower intradialytic plasma potassium.
About 40% of the variability in dialytic potassium removal is not accounted for by the plasma-dialysate potassium gradient (12) . Factors affecting the relative distribution of potassium between the extracellular and intracellular fluid compartments may account for this variance. Both insulin and beta-2 adrenergic agonists stimulate potassium shifts from the extracellular to the intracellular fluid compartment, thereby attenuating the blood-dialysate potassium concentration gradient. Thus dialytic potassium removal is lower when a 200 mg/dl glucose dialysate is used, as compared with dialysis against a glucose-free dialysate (12, 13) . The former maneuver increases plasma insulin concentrations during dialysis (10), thereby promoting intracellular potassium shifts and decreasing the blooddialysate potassium gradient. This observation suggests that dialytic potassium removal may be attenuated if a patient eats before a dialysis session than if he is dialyzed in the fasting state. Similarly, administration of the beta-2 agonist albuterol before a dialysis treatment decreases dialytic potassium removal by about 40% as compared with a control dialysis session (10) . It is not known whether treatment with a nonselective beta-blocker may conversely enhance dialytic potassium removal. Because insulin and albuterol limit dialytic potassium removal, one might anticipate substantial rebound hyperkalemia within a few hours of ending the dialysis session, although this possibility has not been formally evaluated.
The effect of metabolic acidosis on potassium distribution between the extracellular and intracellular fluid compartments has been poorly characterized. Because bicarbonate administration does not stimulate intracellular potassium shifts within the first 3 hours (8, 9), it is unlikely that changes in acid-base status during dialysis affect the magnitude of potassium removal. Dialytic potassium remo-val correlates poorly with predialysis serum bicarbonate and with the intradialytic change in serum bicarbonate (10, 11) . Moreover, potassium removal is similar with bicarbonate and acetate dialysate (11, 13) .
Patients frequently develop hypokalemia during hemodialysis (10, 11) , and this may be aggravated by pretreatment with insulin or albuterol. The potential of intradialytic hypokalemia to induce or aggravate cardiac arrhythmias has not been studied systematically. We observed a mean plasma potassium of 3.1 mmol/liter in the last 2 hours of a control dialysis session; it was significantly lower, at 2.8 mmol/liter, when the dialysis session was preceded by administration of albuterol (10) . During continuous electrocardiographic monitoring, 2 of 7 patients developed rare « 1/min) unifocal PVC's in the control dialysis session. Five of the 7 patients developed rare PVC's in the dialysis session preceded by albuterol (10) . None developed more significant arrhytmias. The clinical significance of these observations remains to be determined; it is unclear whether the higher incidence of PVC's was due to the lower plasma potassium, beta-adrenergic stimulation, or a combination of both factors.
Measures to prevent hyperkalemia should decrease the frequency of severe hyperkalemia requiring emergency hemodialysis. Dietary potassium intake is clearly an important measure in the prevention of hyperkalemia, and requires frequent counseling by the nephrologist and renal dietitian. Nondietary factors may also predispose to hyperkalemia in dialysis patients. Prolonged fasting (> 12-15 hours) in preparation for surgery or radiologic procedures results in significant hyperkalemia, due to potassium shifts from the intracellular to the extracellular fluid compartments (14, 15) . This phenomenon is observed in nondiabetic patients, and may be exaggerated in diabetic patients if they develop significant hyperglycemia when their insulin is withheld. Fasting hyperkalemia can be prevented by the administration of intravenous dextrose (10% dextrose @ 50 ml/h) during the fast (15) . This maneuver stimulates endogenous insulin secretion, thereby promoting potassium shifts into the cells. In diabetic patients (in whom endogenous insulin secretion may not occur) one should add regular insulin (10 units per liter) to the dextrose infusion. Because beta-2 adrenergic agonists drive potassium into the cells, beta-2 blockers predictably increase plasma potassium in dialysis patients (16, 17 Effect of hypertonic versus isotonic sodium bicarbonate on plasma potassium concentration in patients with end-stage
